Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
A Prospective, Multicenter, Randomized Controlled Study of Disitamab Vedotin Plus Toripalimab With or Without Pelvic Lymph Node Dissection for Bladder-Sparing Treatment in Patients With cT2-3N0M0 Bladder Urothelial Carcinoma
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Muscle-invasive bladder cancer is commonly treated with radical cystectomy; however, bladder-sparing strategies are needed for selected patients who decline cystectomy. This study evaluates a bladder-sparing strategy based on maximal transurethral resection of bladder tumor, disitamab vedotin plus toripalimab, and the addition of standardized pelvic lymph node dissection.
Participants will be randomized to receive disitamab vedotin plus toripalimab with or without pelvic lymph node dissection after maximal transurethral resection of bladder tumor. Tumor response will be assessed by imaging, cystoscopy or transurethral resection/biopsy when clinically indicated, and urine cytology. Participants who meet bladder-sparing criteria will enter bladder-intact follow-up according to the protocol. Safety, survival, quality of life, treatment cost, and exploratory biomarkers will also be evaluated.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Hailong Hu
- Telefonnummer: +86 13662096232
- E-mail: huhailong@tmu.edu.cn
Undersøgelse Kontakt Backup
- Navn: Peng Li
- Telefonnummer: +86 18935803489
- E-mail: lipeng990220@tmu.edu.cn
Studiesteder
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300211
- The Second Hospital of Tianjin Medical University
-
Kontakt:
- Peng Li
- Telefonnummer: +86 18935803489
- E-mail: lipeng990220@tmu.edu.cn
-
Kontakt:
- Hailong Hu, MD,PhD
- Telefonnummer: +86 13662096232
- E-mail: huhailong@tmu.edu.cn
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Male or female participants aged 18 years or older.
- Histologically confirmed bladder urothelial carcinoma.
- Clinical stage cT2-3N0M0 according to the AJCC 8th edition TNM staging system.
- HER2 expression of IHC 2+ or higher.
- Participants who decline radical cystectomy as assessed by the investigator.
- Adequate organ function as defined in the study protocol.
- Ability to understand and willingness to sign written informed consent.
Exclusion Criteria:
- Known allergy or hypersensitivity to disitamab vedotin, toripalimab, their excipients, or other monoclonal antibodies.
- Prior radiotherapy for bladder cancer.
- Prior anticancer treatment that may affect efficacy assessment, as defined in the study protocol.
- Pregnant or breastfeeding women.
- Any serious uncontrolled disease or medical condition that, in the investigator's judgment, would make participation inappropriate.
- Participation in another interventional clinical trial that may interfere with this study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Disitamab Vedotin Plus Toripalimab With Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab and standardized pelvic lymph node dissection.
|
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.
Standardized pelvic lymph node dissection will be performed in participants assigned to the PLND arm.
|
|
Aktiv komparator: Disitamab Vedotin Plus Toripalimab Without Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab without planned pelvic lymph node dissection.
|
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
2-year Bladder-intact Event-free Survival Rate
Tidsramme: 24 months after randomization
|
The proportion of participants who remain alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death at 24 months after randomization.
|
24 months after randomization
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Complete Response Rate
Tidsramme: After completion of induction treatment, up to 12 weeks
|
The proportion of participants who achieve clinical complete response, defined as no visible tumor on imaging, no evidence of malignancy on cystoscopy or TURBT/biopsy when clinically indicated, and negative urine cytology.
For participants undergoing pelvic lymph node dissection, no lymph node metastasis is required.
|
After completion of induction treatment, up to 12 weeks
|
|
Partial Response Rate
Tidsramme: After completion of induction treatment, up to 12 weeks
|
The proportion of participants with non-muscle-invasive disease, including Ta, T1, or carcinoma in situ, confirmed by urine cytology or pathological biopsy, with no evidence of locally advanced or metastatic disease on imaging.
|
After completion of induction treatment, up to 12 weeks
|
|
Disease Progression Rate
Tidsramme: Up to 24 months after randomization
|
The proportion of participants with disease progression, defined as muscle-invasive bladder cancer confirmed by pathological biopsy, locally advanced disease, regional lymph node recurrence, distant metastasis, or bladder cancer-related death.
|
Up to 24 months after randomization
|
|
Overall Survival
Tidsramme: Up to 60 months after randomization
|
Overall survival is defined as the time from randomization to death from any cause.
|
Up to 60 months after randomization
|
|
Incidence and Severity of Adverse Events
Tidsramme: From the first dose through 30 days after the last dose, up to approximately 19 months
|
The incidence, severity, and relationship to study treatment of adverse events will be assessed according to the Common Terminology Criteria for Adverse Events.
|
From the first dose through 30 days after the last dose, up to approximately 19 months
|
|
Quality of Life Score
Tidsramme: Baseline to 24 months after randomization
|
Quality of life will be assessed using the EORTC QLQ-C30 questionnaire according to the study protocol.
|
Baseline to 24 months after randomization
|
|
Total Treatment Cost
Tidsramme: From randomization to the end of follow-up, up to 60 months
|
Total treatment cost will be calculated from randomization to the final follow-up according to the study protocol.
|
From randomization to the end of follow-up, up to 60 months
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
2-Year Bladder-Intact Event-Free Survival Rate by Baseline HER2 IHC Category
Tidsramme: 24 months after randomization
|
Pretreatment tumor HER2 expression will be assessed by immunohistochemistry and categorized as IHC 2+ or IHC 3+.
The percentage of participants meeting the 2-year bladder-intact event-free survival definition will be estimated separately for each HER2 IHC category.
Bladder-intact event-free survival is defined as being alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death.
The unit of measure is percentage of participants.
|
24 months after randomization
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Urologiske neoplasmer
- Urinblæresygdomme
- Urinblære neoplasmer
- Kirurgiske procedurer, operative
- Urologiske kirurgiske procedurer
- Urogenitale kirurgiske procedurer
- Disitamab Vedotin
- Toripalimab
- Transuretral resektion af blære
- RC48 -antistof
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- TMU2H-RC48-TORI-MIBC-2026-035
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .